New Anti-VEGF Agent Increases Wet AMD Treatment Options

[ODwire.org NewsBot]

A newly approved intravitreal anti-VEGF therapy may extend treatment intervals for patients with wet age-related macular degeneration. Over the last decade, intravitreal injections of drugs targeting vascular endothelial growth factor (VEGF) have brought new hope to patients with potentially blinding neovascular age-related macular degeneration (AMD). Effective treatment may require injections as often as once a [...]

More...